Abstract
Lipoprotein-associated phospholipase A2 (Lp-PLA2), also named as platelet-activating factor (PAF)-acetylhydrolase, exhibits a Ca2+-independent phospholipase A2 activity and catalyzes the hydrolysis of the ester bond at the sn-2 position of PAF and oxidized phospholipids (oxPL). These phospholipids are formed under oxidative and inflammatory conditions, and may play important roles in atherogenesis. The vast majority of plasma Lp-PLA2 mass binds to low-density lipoprotein (LDL) while a smaller amount is associated with high-density lipoprotein (HDL). Lp-PLA2 is also bound to lipoprotein (a) [Lp(a)], very low-density lipoprotein (VLDL) and remnant lipoproteins. Several lines of evidence suggest that the role of plasma Lp-PLA2 in atherosclerosis may depend on the type of lipoprotein particle with which this enzyme is associated. Data from large Caucasian population studies have supported plasma Lp-PLA2 (primarily LDL-associated Lp-PLA2) as a cardiovascular risk marker independent of, and additive to, traditional risk factors. On the contrary, the HDL-associated Lp-PLA2 may express antiatherogenic activities and is also independently associated with lower risk for cardiac death. The present review presents data on the biochemical and enzymatic properties of Lp-PLA2 as well as its structural characteristics that determine the association with LDL and HDL. We also critically discuss the possible pathophysiological and clinical significance of the Lp- PLA2 distribution between LDL and HDL in human plasma, in view of the results of prospective epidemiologic studies on the association of Lp-PLA2 with future cardiovascular events as well the recent studies that evaluate the possible effectiveness of specific Lp-PLA2 inhibitors in reducing residual cardiovascular risk.
Keywords: Atherosclerosis, Cardiovascular disease, Darapladib, Lipoproteins, LDL, HDL, Lp-PLA2.
Current Pharmaceutical Design
Title:Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL
Volume: 20 Issue: 40
Author(s): Constantinos C. Tellis and Alexandros D. Tselepis
Affiliation:
Keywords: Atherosclerosis, Cardiovascular disease, Darapladib, Lipoproteins, LDL, HDL, Lp-PLA2.
Abstract: Lipoprotein-associated phospholipase A2 (Lp-PLA2), also named as platelet-activating factor (PAF)-acetylhydrolase, exhibits a Ca2+-independent phospholipase A2 activity and catalyzes the hydrolysis of the ester bond at the sn-2 position of PAF and oxidized phospholipids (oxPL). These phospholipids are formed under oxidative and inflammatory conditions, and may play important roles in atherogenesis. The vast majority of plasma Lp-PLA2 mass binds to low-density lipoprotein (LDL) while a smaller amount is associated with high-density lipoprotein (HDL). Lp-PLA2 is also bound to lipoprotein (a) [Lp(a)], very low-density lipoprotein (VLDL) and remnant lipoproteins. Several lines of evidence suggest that the role of plasma Lp-PLA2 in atherosclerosis may depend on the type of lipoprotein particle with which this enzyme is associated. Data from large Caucasian population studies have supported plasma Lp-PLA2 (primarily LDL-associated Lp-PLA2) as a cardiovascular risk marker independent of, and additive to, traditional risk factors. On the contrary, the HDL-associated Lp-PLA2 may express antiatherogenic activities and is also independently associated with lower risk for cardiac death. The present review presents data on the biochemical and enzymatic properties of Lp-PLA2 as well as its structural characteristics that determine the association with LDL and HDL. We also critically discuss the possible pathophysiological and clinical significance of the Lp- PLA2 distribution between LDL and HDL in human plasma, in view of the results of prospective epidemiologic studies on the association of Lp-PLA2 with future cardiovascular events as well the recent studies that evaluate the possible effectiveness of specific Lp-PLA2 inhibitors in reducing residual cardiovascular risk.
Export Options
About this article
Cite this article as:
Tellis C. Constantinos and Tselepis D. Alexandros, Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Bound to LDL and HDL, Current Pharmaceutical Design 2014; 20 (40) . https://dx.doi.org/10.2174/1381612820666140622200916
DOI https://dx.doi.org/10.2174/1381612820666140622200916 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The GH/IGF-1 Axis and Heart Failure
Current Cardiology Reviews Taurine, Bone Growth and Bone Development
Current Nutrition & Food Science Preventing and Treating Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer
Current Cancer Therapy Reviews Editorial [Hot Topic: The Evolution of Cell Therapy Towards Enhancing Vascular Regeneration in the Clinic (Guest Editors: Drew Kuraitis and Erik J. Suuronen)]
Current Vascular Pharmacology Effect of Long Chain n-3 PUFA on Endothelial Activation, Endothelial Function and Atheromatous Plaque Stability
Current Nutrition & Food Science The Anti-Cancer Charm of Flavonoids: A Cup-of-Tea Will Do!
Recent Patents on Anti-Cancer Drug Discovery Objectively Assessed Physical Activity and Sedentary Behaviour During Pregnancy in Portuguese Women: Differences Between Trimesters and Weekdays and Weekends
Current Women`s Health Reviews Evaluating Oxidative Stress in Human Cardiovascular Disease: Methodological Aspects and Considerations
Current Medicinal Chemistry Editorial (Thematic Issue: Focal Atrial Tachycardias and Atrial Flutter: Are they Hot Enough to Make a Thematic Issue?)
Current Cardiology Reviews Critical Review of the Ankle Brachial Index
Current Cardiology Reviews Cardioprotective Role of <i>Theobroma cacao</i> against Isoproterenol-Induced Acute Myocardial Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina
Current Alzheimer Research CD31+ Circulating Angiogenic Cell Number and Subtypes are Reduced in Individuals with Chronic Stroke
Current Neurovascular Research Potential of Nanocarriers in Genetic Immunization
Recent Patents on Drug Delivery & Formulation Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease
Current Pharmacogenomics and Personalized Medicine An Update on “Selenium Containing Compounds from Poison to Drug Candidates: A Review on the GPx-like Activity”
Current Chemical Biology Platelet SERT as a Peripheral Biomarker of Serotonergic Neurotransmission in the Central Nervous System
Current Medicinal Chemistry The Role of Inflammation in Epicardial Adipose Tissue in Heart Diseases
Current Pharmaceutical Design Oxidative Stress and Antioxidative Enzyme Activities in Chronic Kidney Disease and Different Types of Renal Replacement Therapy
Current Protein & Peptide Science Phytosterols and Inflammation
Current Medicinal Chemistry